FIELD: medicine.
SUBSTANCE: method for prediction of esophageal cancer progression differs by the fact that the percentage of CD3+CD8+, T regs (CD4+CD25+CD127dim) subpopulations lymphocytes is determined by flow cytometry in the homogenates of tumour tissue samples and visually unchanged tissue (the peritumoral zone and the resection line) taken in the operation for the primary esophageal cancer, the coefficients K1=PZ/TT, K2=PZ/RL and K3=RL/TT are calculated, where PZ is the peritumoral zone, TT is the tumour tissue, RL is the resection line, and for K1 values for T regs above 0.343, K2 for T regs above 2.37 and K3 for CD3+CD8+cells below 1.198, progression of esophageal cancer is predicted.
EFFECT: method allows to increase the accuracy and informative value of the esophageal cancer progression prediction.
1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INDIVIDUAL PREDICTION OF PROGRESSION OF SQUAMOUS CELL ESOPHAGUS CANCER II-III STAGE AFTER SURGICAL TREATMENT | 2019 |
|
RU2712921C1 |
| METHOD OF PREDICTING RECURRENT SOFT TISSUE SARCOMAS | 2016 |
|
RU2625035C1 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| EXPANSION OF LYMPHOCYTE WITH A CYTOKINE COMPOSITION FOR ACTIVE CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2739770C2 |
| METHOD FOR LOCAL-DISTRIBUTED COLON CANCER METASTASIS | 2016 |
|
RU2619340C1 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| METHOD OF OBTAINING A CULTURE OF LYMPHOCYTES ENRICHED IN TUMOR-SPECIFIC T-LYMPHOCYTE CLONES AND CELL CULTURES OBTAINED USING THE SPECIFIED METHOD | 2022 |
|
RU2808595C1 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHOD FOR DETERMINING QUALITATIVE PARAMETERS OF IMMUNOSUPPRESSIVE CELLS IN CANCER PATIENTS | 2020 |
|
RU2752973C1 |
| METHOD OF PRODUCING ANTIGEN-SPECIFIC CYTOTOXIC CELLS HAVING ACTIVITY AGAINST BREAST CANCER CELLS | 2013 |
|
RU2596920C2 |
